8-Anilino-1-naphthalenesulfonic acidCAS# 82-76-8 |
2D Structure
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 82-76-8 | SDF | Download SDF |
PubChem ID | 1369 | Appearance | Powder |
Formula | C16H13NO3S | M.Wt | 299.3 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 8-anilinonaphthalene-1-sulfonic acid | ||
SMILES | C1=CC=C(C=C1)NC2=CC=CC3=C2C(=CC=C3)S(=O)(=O)O | ||
Standard InChIKey | FWEOQOXTVHGIFQ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C16H13NO3S/c18-21(19,20)15-11-5-7-12-6-4-10-14(16(12)15)17-13-8-2-1-3-9-13/h1-11,17H,(H,18,19,20) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
8-Anilino-1-naphthalenesulfonic acid Dilution Calculator
8-Anilino-1-naphthalenesulfonic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.3411 mL | 16.7056 mL | 33.4113 mL | 66.8226 mL | 83.5282 mL |
5 mM | 0.6682 mL | 3.3411 mL | 6.6823 mL | 13.3645 mL | 16.7056 mL |
10 mM | 0.3341 mL | 1.6706 mL | 3.3411 mL | 6.6823 mL | 8.3528 mL |
50 mM | 0.0668 mL | 0.3341 mL | 0.6682 mL | 1.3365 mL | 1.6706 mL |
100 mM | 0.0334 mL | 0.1671 mL | 0.3341 mL | 0.6682 mL | 0.8353 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Peri acid
Catalog No.:BCC9116
CAS No.:82-75-7
- Visnagin
Catalog No.:BCN4367
CAS No.:82-57-5
- 1-Amino-2-methylanthraquinone
Catalog No.:BCC8451
CAS No.:82-28-0
- Alpha-Toxicarol
Catalog No.:BCN6467
CAS No.:82-09-7
- Rottlerin
Catalog No.:BCC7127
CAS No.:82-08-6
- Benzanthrone
Catalog No.:BCC8845
CAS No.:82-05-3
- Khellin
Catalog No.:BCN4356
CAS No.:82-02-0
- Lancerin
Catalog No.:BCN2803
CAS No.:81991-99-3
- Vitedoin A
Catalog No.:BCN6741
CAS No.:819861-40-0
- Hyperxanthone E
Catalog No.:BCN8072
CAS No.:819860-76-9
- KW-2478
Catalog No.:BCC2127
CAS No.:819812-04-9
- Clovin
Catalog No.:BCN7817
CAS No.:81970-00-5
- Daurichromenic acid
Catalog No.:BCN4355
CAS No.:82003-90-5
- 10Z-Hymenialdisine
Catalog No.:BCC5773
CAS No.:82005-12-7
- Boc-Leucinol
Catalog No.:BCC2724
CAS No.:82010-31-9
- Loteprednol etabonate
Catalog No.:BCC4916
CAS No.:82034-46-6
- NSC 33994
Catalog No.:BCC2441
CAS No.:82058-16-0
- JNJ 17203212
Catalog No.:BCC7668
CAS No.:821768-06-3
- CMK
Catalog No.:BCC1489
CAS No.:821794-90-5
- FMK
Catalog No.:BCC1580
CAS No.:821794-92-7
- Andropanoside
Catalog No.:BCN4570
CAS No.:82209-72-1
- Andrographiside
Catalog No.:BCN4569
CAS No.:82209-76-5
- Atomoxetine HCl
Catalog No.:BCC5046
CAS No.:82248-59-7
- Impurity C of Alfacalcidol
Catalog No.:BCC5385
CAS No.:82266-85-1
Cysteamine functionalized MoS2 quantum dots inhibit amyloid aggregation.[Pubmed:30716371]
Int J Biol Macromol. 2019 May 1;128:870-876.
In this study, cysteamine-functionalized molybdenum disulfide quantum dots (MoS2 QDs) were synthesized by a one-pot hydrothermal method. A range of techniques including of Thioflavin T and 8-Anilino-1-naphthalenesulfonic acid fluorescence assays, circular dichroism, and transmission electron microscope have been employed to determination the efficacy of MoS2 QDs on the inhibition/reversion of fibrillation and hindering cytotoxicity induced by protofibrils and amyloid fibrils of bovine serum albumin (BSA). Results demonstrated that MoS2 QDs could effectively inhibit the fibrillogenesis and destabilize preformed fibrils of BSA in a concentration-dependent manner. Cytotoxicity protection and imagine on Hela cells was investigated using the methyl thiazolyl tetrazolium (MTT) assay. It was found that MoS2 QDs not only has good biocompatibility, low toxicity and good cell penetration, but also could effectively decrease the cytotoxicity caused by the formed fibrils of BSA. The results obtained in this work suggested the potential biological application of MoS2 QDs in therapeutics and provided new insight into the design of multifunctional nanomaterials for amyloid-related diseases.
Effects of Ser47-Point Mutation on Conformation Structure and Allergenicity of the Allergen of Der p 2, a Major House Dust Mite Allergen.[Pubmed:30479083]
Allergy Asthma Immunol Res. 2019 Jan;11(1):129-142.
PURPOSE: Hypoallergenic recombinant Der p 2 has been produced by various genetic manipulations, but mutation of a naturally polymorphic amino acid residue known to affect IgE binding has not been studied. This study aimed to determine the effect of a point mutation (S47W) of residue 47 of Der p 2 on its structure and immunoglobulin (Ig) E binding. Its ability to induce pro-inflammatory responses and to induce blocking IgG antibody was also determined. METHODS: S47 of recombinant Der p 2.0110, one of the predominant variants in Bangkok, was mutated to W (S47W). S47W secreted from Pichia pastoris was examined for secondary structure and for the formation of a hydrophobic cavity by 8-Anilino-1-naphthalenesulfonic acid (ANS) staining. Monoclonal and human IgE-antibody binding was determined by enzyme-linked immunosorbent assay. Allergen-induced degranulation by human epsilon receptor expressed-rat basophil was determined. Stimulation of the pro-inflammatory cytokine interleukin (IL)-8 release from human bronchial epithelial (BEAS2B) cells and inhibition of IgE binding to the wild type allergen by S47W-induced IgG were determined. RESULTS: S47W reduced secondary structure and failed to bind the hydrophobic ANS ligand as well as a monoclonal antibody known to be dependent on the nature of the side chain of residue 114 in an adjacent loop. It could also not stimulate IL-8 release from BEAS2B cells. IgE from house dust mite (HDM)-allergic Thais bound S47W with 100-fold weaker avidity, whereas IgE of HDM-allergic Australians did not. S47W still induced basophil degranulation, although requiring higher concentrations for some subjects. Anti-S47W antiserum-immunized mice blocked the binding of human IgE to wild type Der p 2. CONCLUSIONS: The mutant S47W had altered structure and reduced ability to stimulate pro-inflammatory responses and to bind IgE, but retained its ability to induce blocking antibodies. It thus represents a hypoallergen produced by a single mutation of a non-solvent-accessible amino acid.
Proline functionalized gold nanoparticles modulates lysozyme fibrillation.[Pubmed:30476794]
Colloids Surf B Biointerfaces. 2019 Feb 1;174:401-408.
Amyloid fibrils are the hallmarks of neurodegenerative diseases like Alzheimer's, Parkinson's and other proteopathies. Inhibition of fibrillation is a potential strategy to check the progress of amyloid associated diseases and further allied deterioration. In this study, we have synthesized proline functionalized gold nanoparticles (Pro-AuNPs) and scrutinized its antifibrillation property towards Hen Egg White Lysozyme (HEWL) aggregation. Pro-AuNPs were characterized using various biophysical methods like ultraviolet-visible spectroscopy, fourier transform infra-red spectroscopy, zeta potential measurement, dynamic light scattering and transmission electron microscopy. The effect of Pro-AuNPs on HEWL fibrillation was analyzed employing thioflavin T (ThT) and 8-Anilino-1-naphthalenesulfonic acid (ANS) assays. The kinetics of HEWL exhibited a typical sigmoidal nature of protein aggregation and was fitted to Boltzmann model. HEWL in the presence of bare gold nanoparticles (bAuNPs) exhibited similar aggregation kinetics as HEWL alone. However, HEWL fibrillation substantially reduced upon co-incubation with proline and Pro-AuNPs, and two slightly different intermediate species were formed with these two systems as predicted by CD spectroscopy. TEM images also supported the above observation displaying different morphological states of HEWL aggregates in the presence of proline and Pro-AuNPs. Using computational methods, the nature of interaction of HEWL and proline was found to be hydrogen bonding and hydrophobic interaction in multiple amyloidogenic regions. These interactions inhibited the formation of prefibrils (beta-sheet rich intermediates) and also found to disintegrate fibrils. Furthermore, HEWL-Pro-AuNPs system resulted HEWL adsorption through hydrophobic patches, which blocked the intermolecular beta-sheet formation. The present study successfully established Pro-AuNPs as a potential inhibitor of HEWL aggregation.